The FDA approved a new treatment option for adult patients facing Adjuvant Muscle-Invasive Bladder Cancer (MIBC). Genentech announced the regulatory clearance for Tecentriq and Tecentriq Hybreza. This application serves individuals who have circulating tumor DNA molecular residual disease after undergoing a cystectomy. Doctors identify these high-risk patients using Natera’s Signatera CDx personalized assay. Notably, this milestone represents the eleventh indication for Tecentriq in the United States.
Levi Garraway, M.D., Ph.D., explained how this testing improves medical choices.
“Combining our cancer immunotherapy Tecentriq with state-of-the-art MRD testing allows more precise identification of patients who are candidates for intervention and those who might safely avoid unnecessary treatment.”
The Chief Medical Officer and Head of Global Product Development expressed excitement for the deployment of this tool.
“We look forward to delivering this first-of-its-kind ctDNA-guided regulatory approval to bladder cancer physicians and patients in the U.S.”
Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network, spoke on how this innovation relieves the emotional strain on families.
“For the patients and families, the ‘watch and wait’ period after a cystectomy is often defined by uncertainty. This ctDNA-guided approach can enable doctors to use serial ctDNA MRD testing to identify who is at a higher risk of recurrence and move quickly toward immunotherapy for those who may benefit from it, while allowing others to safely avoid additional treatment and its associated side effects.”
Positive Survival Outcomes in IMvigor011
Globally, over 150,000 individuals receive an MIBC diagnosis every year and undergo bladder removal surgery. Unfortunately, nearly half of these patients experience a return of their cancer. Historically, medical teams utilized tumor staging to choose postoperative care. The Phase III IMvigor011 study evaluated a different method using molecular tracking.
This clinical trial monitored 761 people with serial testing during the first year after surgery. Ultimately, 250 individuals tested positive for ctDNA and entered the treatment phase. The investigation showed that Tecentriq lowered the risk of disease recurrence or death by 36%. Furthermore, the drug cut the risk of death by 41% in patients with detectable ctDNA.
The medicine works as a monoclonal antibody that binds directly to the PD-L1 protein. This pathway blocks interactions with PD-1 and B7.1 receptors to re-activate T cells. However, the drug can cause the immune system to attack normal organs. Patients must monitor for lung, liver, or intestinal complications. The most common side effects include feeling tired, a cough, and decreased appetite. Patients must also undergo pregnancy screening before beginning this therapy.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
